If you have spent any time looking into medical cannabis in the UK, you have likely encountered a sea of conflicting information. Some sources claim it is a "miracle cure," while others treat it as a controversial grey area. To understand the reality, we first need to establish what we are talking about.
Before we dive into the clinical pathway, let’s define two critical terms:
- Specialist: A doctor who has completed higher specialist training and is registered on the General Medical Council (GMC) Specialist Register. In the context of medical cannabis, they must be a specialist consultant. A standard GP cannot prescribe these medications. Prescription: A formal, legal instruction written by an authorised healthcare professional, which allows a patient to be supplied with a specific medicine, including the dosage and frequency of use.
The legal reality: CBMPs vs. recreational cannabis
Since 1 November 2018, it has been legal for specialist doctors to prescribe Cannabis-Based Medicinal Products (CBMPs) in the UK. However, there is a common misconception that this means "legal weed." It does not.
Recreational cannabis—often sold on the illicit market—is unregulated, contains unknown levels of THC and CBD, and may be contaminated with heavy metals or pesticides. In contrast, CBMPs are pharmaceutical-grade products manufactured to strict quality standards (GMP or Good Manufacturing Practice). They are subject to rigorous testing and are treated as controlled drugs, similar to strong opioids or stimulants used for ADHD.
Here is the bit people miss: Medical cannabis is not a "first-line" treatment in the UK. Under the National Institute for Health and Care Excellence (NICE) guidelines, specifically NICE NG144, medical cannabis is generally only considered when standard licensed treatments have failed or have proven unsuitable for the patient.
Is it treated like a "normal" medicine?
In practice, yes and no. It follows the same legal trajectory as other controlled medications, requiring an audit trail, clinical justification, and ongoing monitoring. However, because it is rarely prescribed on the NHS, most patients access it via the private sector. This creates a different patient experience compared to walking into a high-street pharmacy with a green NHS prescription form.
The digital pathway: Telehealth and eligibility
Most patients today access CBMPs through private clinics that utilise telehealth systems. Because these clinics must adhere to strict clinical governance, the first step is almost always an online eligibility form.
These forms act as a triage tool. They do not grant a prescription—a prescription can only be issued by a doctor after a consultation. Instead, these forms filter out patients who clearly do not meet the criteria, such as those who have not tried existing licensed treatments or those with contraindications (for example, a history of psychosis).
The process usually follows this structure:
Screening: Completion of an online eligibility form. Evidence collection: The clinic requests a Summary Care Record (SCR) from your GP to verify your medical history. Consultation: A 30-to-60-minute video call with a specialist consultant. MDT Review: In many clinics, the prescription must be approved by a Multi-Disciplinary Team (MDT) to ensure clinical oversight of the CBMP. Dispensing: The prescription is sent to a specialised pharmacy and sent to the patient’s home via courier.The transparency problem: Why you won't find price lists
One of the most frequent complaints from patients is the lack of transparent pricing on clinic websites. You might find a consultation fee, but the cost of the actual medication is often obscured. There is a very specific, boring, and legal reason for this.
In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) has strict regulations regarding the advertising of prescription-only medicines (POMs). Under the Human Medicines Regulations 2012, it is illegal to advertise a prescription-only medicine to the general public. Because CBMPs are classified as POMs, clinics are walking a tightrope.
Here is the bit people miss: While clinics can list their service fees (consultations, repeat prescriptions), listing the exact prices of specific cannabis products risks being interpreted as "advertising" a medication. While this protects the public from pharmaceutical marketing, it creates a significant barrier for patients trying to budget for their treatment.
Clinical oversight and ongoing monitoring
Once you are prescribed a CBMP, the relationship with the clinic does not end. This is where medical cannabis mirrors "normal" medicine. You are not simply given a prescription and left to your own devices. Ongoing monitoring is a legal and ethical requirement.
Your specialist must ensure that the treatment is: 1) effective for your symptoms, and 2) not causing adverse side effects. This involves periodic follow-up appointments, often every three months, to review your progress. If you aren't seeing an improvement, a responsible clinician will discuss stopping the treatment or adjusting the dosage—exactly as they would with antidepressants or blood pressure medication.
Comparison Table: Conventional Medicine vs. Medical Cannabis
Feature Conventional NHS Medicine Medical Cannabis (CBMP) Prescriber GP or Hospital Consultant GMC Specialist Consultant ONLY Access NHS Pharmacy Private Specialist Pharmacy Guidance NICE Licensed Guidelines NICE NG144 & Specialist Discretion Monitoring GP/Nurse Reviews Specialist/Clinic Reviews Legal Status Controlled or Uncontrolled Schedule 2 Controlled DrugManaging expectations: Evidence-based framing
It is crucial to avoid overpromising medical outcomes. Medical cannabis is not a panacea. For some patients, it is transformative; for others, it provides only modest relief. Furthermore, because the industry is still relatively young, the long-term clinical data is still being gathered.
When you speak to a consultant, they should be able to explain the evidence for your specific condition. If a clinic or a representative tells you that medical cannabis will "definitely cure" a chronic condition, that is a red flag. Legitimate clinical practice focuses on symptom management, functional improvement, and quality of life—not miracle cures.
Final thoughts: Is it "normal"?
Is medical cannabis treated like a normal medicine? If you look at the bureaucracy, the clinical standards, and the requirement for a specialist's signature, the answer https://www.smiletotalk.com/blog/5-evidence-based-facts-about-medical-cannabis-for-people-in-the-uk is yes. It is a strictly controlled, evidence-based pathway designed to protect patient safety.
However, the lack of widespread NHS funding and the inability to openly discuss pricing makes the experience feel very "abnormal" compared to standard primary care. For the patient, it requires a high degree of self-advocacy, an understanding of the patient assessment process, and a willingness to engage in ongoing monitoring with a clinic that prioritises clinical excellence over sales targets.
If you are considering this path, do your research on the clinic’s CQC (Care Quality Commission) rating, ensure they have a transparent process for clinical oversight of the CBMP, and always, always prioritise a consultation with a specialist who is willing to discuss the limitations of treatment as openly as the benefits.